BEQALZI efficacy

After prior treatment with a BTKi therapy

Patients achieved deep and rapid and durable responses with BEQALZI

ORR ASSESSED BY IRC (primary endpoint; N=103)^1,2

Median follow-up: 14.2 months

Percentages may not sum to total due to rounding.

mTTR ASSESSED BY IRC^1,2

1.9 months

(secondary endpoint; range: 1.6, 6.2)

TTR was defined as time from treatment initiation to first documented response.²

ORR ACROSS SUBGROUPS, INCLUDING HIGH-RISK FEATURES²*

Exploratory analyses

BEQALZI™ (sonrotoclax) overall response rate across high-risk subgroups forest plot

All subgroup analyses are exploratory and descriptive in nature.

*The ORR in historical control was assumed to be 30% based on real-world efficacy data in the post–BTKi setting (represented by the dotted line in the subgroup-analysis forest plot above).^2-5

^†TP53 subgroup analyses are limited, as 32% of patients had missing information.²

Durable responses

BEQALZI DOR ASSESSED BY IRC (secondary endpoint; N=54)^1,2‡

Median follow-up: 11.9 months

BEQALZI™ (sonrotoclax) duration of response graph

DURATION OF RESPONSE AT 9 MONTHS²

63%

(95% CI: 48, 75)

of patients who responded continued to exhibit a clinically meaningful response with BEQALZI at 9 months

^‡Estimated by the Kaplan-Meier method.¹

BTKi=Bruton’s tyrosine kinase inhibitor; CR=complete response; DOR=duration of response; IRC=independent review committee; LDi=longest diameter; mDOR=median duration of response; mTTR=median time to response; NE=not estimable; ORR=overall response rate; PD=progressive disease; PR=partial response; QD=once daily; sMIPI=simplified Mantle cell lymphoma International Prognosis Index score; TTR=time to response.

Study design Safety

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

BEQALZI is contraindicated with strong CYP3A inhibitors at initiation and during the ramp-up phase due to the potential for an increased risk of tumor lysis syndrome (TLS).

WARNINGS & PRECAUTIONS

Tumor Lysis Syndrome (TLS):

BEQALZI can cause rapid tumor reduction and changes in blood chemistries consistent with TLS, which may be serious or life-threatening and require prompt management. TLS may occur as early as 4 hours after the first dose, with dose increases, or upon reinitiation following treatment interruption. Laboratory or clinical TLS occurred in 7% of patients who followed the recommended dose ramp-up. Assess all patients for TLS risk and initiate prophylaxis, including adequate hydration and antihyperuricemics. For patients at high risk of TLS, consider hospitalization with intravenous hydration and employ frequent monitoring. Monitor blood chemistries closely and manage abnormalities promptly. Interrupt BEQALZI for TLS; upon reinitiation, follow dose modification guidance in the Prescribing Information.

Serious Infections:

BEQALZI can cause fatal or serious infections. Serious infections occurred in 14% of patients; Grade 3-4 occurred in 17% (fatal: 2.6%). The most common Grade 3 or greater infection was pneumonia (10%). Monitor for signs and symptoms of infection and treat appropriately. Consider prophylactic antimicrobials and immunoglobulins. Interrupt, reduce dose, or permanently discontinue BEQALZI based on severity.

Neutropenia:

BEQALZI can cause serious or severe cytopenias, including neutropenia. Grade 3 or 4 decreases in neutrophils occurred in 18% of patients (Grade 4: 6%); febrile neutropenia occurred in 1.7% of all patients. Monitor complete blood counts throughout treatment. Interrupt treatment, reduce the dose, or permanently discontinue BEQALZI based on severity.

Embryo-Fetal Toxicity:

BEQALZI can cause fetal harm when administered to pregnant women. Advise patients of the potential risk to a fetus. Verify pregnancy status prior to initiation. Advise females to use effective contraception and males with female partners of reproductive potential to use effective contraception during treatment and for 1 week after the last dose.

ADVERSE REACTIONS

The most common adverse reactions (≥15%) are pneumonia (16%) and fatigue (16%). The most common Grade 3-4 laboratory abnormalities (≥15%) are decreases in lymphocytes (29%) and neutrophils (18%).

DRUG INTERACTIONS

Strong or Moderate CYP3A Inhibitors:

Concomitant use increases BEQALZI exposure. Avoid use of strong CYP3A inhibitors during BEQALZI initiation and ramp-up. Avoid use of moderate CYP3A inhibitors at the 1 mg and 2 mg doses; for all other doses, reduce the BEQALZI dose with concomitant use. See approved labeling for dose modifications.

Strong or Moderate CYP3A Inducers:

Concomitant use decreases BEQALZI exposure. Avoid use.

SPECIAL POPULATIONS

Lactation: Advise women not to breastfeed during treatment with BEQALZI and for 1 week after the last dose.

To report SUSPECTED ADVERSE REACTIONS, contact BeOne Medicines at 1-877-828-5596 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information.

INDICATION

BEQALZI™ (sonrotoclax) is a BCL-2 inhibitor indicated for the treatment of adult patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a Bruton’s tyrosine kinase (BTK) inhibitor.

This indication is approved under accelerated approval based on response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

Please see full Prescribing Information.

References: 1. BEQALZI. Prescribing Information. BeOne Medicines USA, Inc.; 2026. 2. Eyre TA, Song Y, Hermine O, et al. Phase I/II study of sonrotoclax (BGB-11417) monotherapy in patients with mantle cell lymphoma previously treated with anti-CD20 therapy and a Bruton tyrosine kinase inhibitor. J Clin Oncol. Published online July 1, 2026. doi:10.1200/JCO-26-00550 3. Martin P, Maddocks K, Leonard JP, et al. Postibrutinib outcomes in patients with mantle cell lymphoma. Blood. 2016;127(12):1559-1563. 4. Wang M, Schuster SJ, Phillips T, et al. Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004). J Hematol Oncol. 2017;10(1):171. 5. Jain P, Kanagal-Shamanna R, Zhang S, et al. Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib. Br J Haematol. 2018;183(4):578-587.